eligibility_summary
Eligibility: Adults 18–70 (inclusive), ECOG 0–1, CD20+ B‑NHL (WHO 2016) incl DLBCL and transformed FL, relapsed/refractory after ≥2 lines or post auto‑HSCT, previously treated with anthracyclines and rituximab/other anti‑CD20. Exclude active HBV/HCV (detectable DNA/RNA), HIV, positive syphilis serology, CNS‑only lymphoma, prior CAR‑T/engineered T cells (except prior CD19 CAR‑T with SD at 3 mo or any PD), prior CARB vaccination.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial type: observational translational study in relapsed/refractory B‑cell NHL. Interventions/drugs: 1) LY007 CD20 CAR‑T cell infusion (autologous, genetically engineered cellular therapy). Mechanism: CAR with anti‑CD20 scFv redirects patient T cells to recognize CD20 on malignant B cells, triggering T‑cell activation, cytokine release, cytotoxic killing, and in vivo expansion. 2) Commercial CD19 CAR‑T (China) as a comparison cohort (autologous CAR‑T targeting CD19 with the same TCR‑independent killing mechanism). Concomitant (not study drug): BTK inhibitors in some patients, BTK blockade reduces B‑cell receptor signaling. Targets/cells/pathways studied: CD20+ or CD19+ malignant B cells, circulating and tumor‑infiltrating T cells, CAR‑T activation, proliferation, cytotoxicity, and exhaustion states, tumor microenvironment composition, signals linked to BCR/BTK (when BTKi used). Analyses: mass cytometry and single‑cell sequencing of blood and tumor.